Document Detail


Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.
MedLine Citation:
PMID:  22041918     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Several studies have described factors associated with the failure of proton pump inhibitors (PPIs) to effect endoscopic healing of reflux esophagitis (RE), but few studies have addressed factors promoting PPI-based endoscopic healing. We performed post hoc analysis of a multicenter prospective cohort of RE patients to identify factors encouraging endoscopic healing of this disorder.
METHODS: Patients with RE received 10 or 20 mg rabeprazole for 8 weeks, and endoscopic findings before and after treatment were studied. To evaluate the effects of patient background factors on endoscopic healing, we performed multiple logistic regression analysis and determined the respective odds ratios (ORs) and 95% confidence intervals (CIs).
RESULTS: A total of 454 patients who underwent endoscopy at baseline and again at week 8 were included in the analysis. After 8 weeks of treatment, improvement in endoscopic findings was observed in 94.1% (427/454) of patients, and endoscopic healing was seen in 76.7% (348/454). Multiple logistic regression analysis revealed that a combination of angiotensin II receptor blockers (ARBs) had a significant positive impact on endoscopic healing (OR 3.9, 95% CI 1.411-10.903), but no significant positive relationship was seen for other concomitant drugs such as nonsteroidal anti-inflammatory drugs and calcium channel blockers. Severe RE at baseline (OR 0.365, 95% CI 0.281-0.475) and PPI therapy prior to enrollment (OR 0.154, 95% CI 0.052-0.453) were found to have significant negative effects on endoscopic healing.
CONCLUSIONS: Concomitant use of ARBs may promote endoscopic healing of RE treated with PPIs.
Authors:
Hiroto Miwa; Michio Hongo; Motoyasu Kusano;
Related Documents :
11692058 - Twenty-four-hour ph monitoring is required to confirm acid reflux suppression in patien...
16504878 - Long-term outcome of esophagectomy for high-grade dysplasia or cancer found during surv...
10437838 - Thoracoscopic versus laparoscopic modified heller myotomy for achalasia: efficacy and s...
20448378 - Delay in the diagnosis of esophageal carcinoma: experience of a single unit from a deve...
19563288 - Coronally advanced flap with and without vertical releasing incisions for the treatment...
21441418 - Arthroscopic reconstruction of the anterior cruciate ligament with hamstring tendon aut...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2011-11-01
Journal Detail:
Title:  Journal of gastroenterology     Volume:  47     ISSN:  1435-5922     ISO Abbreviation:  J. Gastroenterol.     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-29     Completed Date:  2012-07-23     Revised Date:  2013-04-16    
Medline Journal Info:
Nlm Unique ID:  9430794     Medline TA:  J Gastroenterol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  249-55     Citation Subset:  IM    
Affiliation:
Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. miwahgi@hyo-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage,  therapeutic use
Adolescent
Adult
Aged
Angiotensin Receptor Antagonists / administration & dosage,  therapeutic use*
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage,  therapeutic use
Calcium Channel Blockers / administration & dosage,  therapeutic use
Cohort Studies
Dose-Response Relationship, Drug
Drug Therapy, Combination
Esophagitis, Peptic / drug therapy*,  pathology
Esophagoscopy*
Female
Humans
Logistic Models
Male
Middle Aged
Prospective Studies
Proton Pump Inhibitors / administration & dosage,  therapeutic use*
Severity of Illness Index
Treatment Outcome
Young Adult
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Angiotensin Receptor Antagonists; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Calcium Channel Blockers; 0/Proton Pump Inhibitors; 32828355LL/rabeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic Herpes Zoster Duplex Bilateralis.
Next Document:  Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways...